Pharmacokinetics of a new immediate-release methadone tablet formulation with decreased in vitro solubility

Clinical Drug Investigation

Volumn 32, Issue 7, 2012, Pages 487-495

  Vinson, Robert K ^a  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

Methadone; pharmacokinetics

Indexed keywords

METHADONE; NALTREXONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CANADA; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; FASTING; FEMALE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; METHADONE; MODELS, BIOLOGICAL; SOLUBILITY; TABLETS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84862010992     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11633550-000000000-00000     Document Type: Article

References (28)

1. Mercadante S, Casuccio A, Fulfaro F. et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: A prospective study. J Clin Oncol 2001; 19: 2898-904 (Pubitemid 32538200)
2. Leppert W. The role of methadone in cancer pain treatment: A review. Int J Clin Pract 2009; 63: 1095-109
3. Nicholson AB. Methadone for cancer pain. Cochrane Database Syst Rev 2007; 17: CD003971
4. Mizoguchi H, Watanabe C, Yonezawa A. et al. New therapy for neuropathic pain. Int Rev Neurobiol 2009; 85: 249-60
5. Mannino R, Coyne P, Swainey C. et al. Methadone for cancer-related neuropathic pain: A review of the literature. J Opioid Manag 2006; 2: 269-76
6. Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother 2009; 10: 1727-40
7. KleberHD. Pharmacologic treatments for opioid dependence: Detoxification and maintenance options. Dialogues Clin Neurosci 2007; 9: 455-70 (Pubitemid 351154632)
8. Iribarne C, Berthou F, Baird S. et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996; 9: 365-73 (Pubitemid 26079977)
9. Moody DE, Alburges ME, Parker RJ. et al. The involvement of cytochrome P450 3A4 in the N-demethylation of l-a-acetylmethadol (laam), norlaam, and methadone. Drug Metab Dispos 1997; 25: 1347-53 (Pubitemid 28010919)
10. Davis MP, Walsh D. Methadone for relief of cancer pain: A review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 2001; 9: 73-83 (Pubitemid 32246453)
11. Wang SC, Ho IK, Tsou HH. et al. CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer. J Clin Psychopharmacol 2011; 31: 463-9
12. Bunten H, Liang WJ, Pounder D. et al. CYP2B6 and OPRM1 gene variations predict methadone-related deaths. Addict Biol 2011; 16: 142-4
13. Bruera E, Sweeney C. Methadone use in cancer patients with pain: A review. J Palliative Med 2002; 5: 127-38 (Pubitemid 34111584)
14. Wolff K, Rostami-Hodjegan A, Shires S. et al. The pharmacokinetics of methadone in healthy subjects and opiate users. Br J Clin Pharmacol 1997; 44: 325-34 (Pubitemid 27402106)
15. Foster DJ, Somogyi AA, White JM. et al. Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. Br J Clin Pharmacol 2004; 57: 742-55 (Pubitemid 38748042)
16. Plummer JL, Gourlay GK, Cherry DA. et al. Estimation of methadone clearance: Application in the management of cancer pain. Pain 1988; 33: 313-22
17. Metadol (methadone hydrochloride): Canadian Product Monograph. Montreal: Paladin Labs Inc., 2003
18. Lynch ME. A review of the use of methadone for the treatment of chronic noncancer pain. Pain Res Manage 2005; 10: 133-44 (Pubitemid 41699985)
19. Betancourt AO, Gosselin, PM, Vinson RK. New immediate release formulation for deterring abuse of methadone. Pharmaceutical Development and Technology. Epub 2012 Apr 27 DOI: 10.3109/10837450.2012.680598
20. United States Pharmacopeia/ National Formulary February 1, 2011 [online]. Available from URL: http://www.uspnf.com/uspnf/pub/index?usp=33&inf= 28&s=2&officialOn= [Accessed 2011 Apr 18]
21. Webster L. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Med 2009; 10: S124-33
22. Raffa RB, Pergolizzi JV. Opioid formulations designed to resist/deter abuse. Drugs 2010; 70: 1657-75
23. Gourevitch MN, Hartel D, Tenore P. et al. Three oral formulations of methadone: A clinical and pharmacodynamic comparison. J Subst Abuse Treat 1999; 17: 237-41 (Pubitemid 29459104)
24. Dale O, Hoffer C, Sheffels P. et al. Disposition of nasal, intravenous, and oral methadone in healthy volunteers. Clin Pharmacol Ther 2002; 72: 536-45 (Pubitemid 36237725)
25. Inturrisi CE, Verebely K. Disposition of methadone in man after a single oral dose. Clin Pharmacol Ther 1972; 13: 923-30
26. Kukanich B, Lascelles BD, Aman AM. et al. The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. J Vet Pharmacol Ther 2005; 28: 461-6 (Pubitemid 41530773)
27. Silver JS, Shaffer HJ. Change intolerance to shifts in methadone formulation: A preliminary investigation. J Subst Abuse Treat 1996; 13: 331-9 (Pubitemid 27146575)
28. Steels MD, Hamilton M, McLean PC. The consequences of a change in formulation of methadone prescribed in a drug clinic. Br J Addict 1992; 87: 1549-54